Tailoring polymeric micelles for improved olaparib solubility and drug release

FHS
May 23, 2024
8:24 pm

Olaparib is a selective poly (ADP-ribose) polymerase inhibitor. However, its clinical application is hindered by low solubility and undesired pharmacokinetic profiles (e.g., relatively short circulation).

ESCMID 2024: Drug resistance in fungi – a growing issue – Pharmaceutical Technology

An artistic illustration of Candida fungi. Candida parapsilosis is responsible for the vast majority of Candidemia infections. Image credit: Shutterstock/ Vikks At the 34th European

May 2, 2024

GSK’s mRNA flu shot is heading to Phase 3; Summit’s $235M offering

Plus, news about Oruka Therapeutics, Centessa, Takeda, Innate Pharma and Liquidia: GSK’s mRNA flu vaccine succeeds against both strains in Phase 2: The pharma company

September 13, 2024

The subject no expert wants to write an op-ed on

Every day, my inbox bursts with opinions about everything from poop transplants to climate change. When news in medicine happens, someone will inevitably email me

October 27, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.